Device Trial Radar · NCT02767401
The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)
Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Sep 15, 2015
Primary completion
Aug 15, 2018
Study completion Dec 15, 2018
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Dalian Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Anzhen Hospital; First Hospital of China Medical University; Nanfang Hospital, Southern Medical University
- First posted
- May 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on myocardial viability in coronary artery disease patients with single coronary total occlusion (CTO) lesions.
Conditions
- Hibernation, Myocardial
- Complete Occlusion of Coronary Artery
Interventions
stenting or balloon expansionDevice
all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betalocDrug
Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes to myocardial viabilityTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.